Artiva Biotherapeutics, Inc. (ARTV) Form 8-K — Oct 27, 2026
$ARTVForm 8-KItems 2.02, 2.05, 9.01Filed Oct 27, 2026, 8:30 AM ET0001193125-26-432806Original filing
Artiva Biotherapeutics is halting all further development of AlloNK (AB-101), its lead allogeneic NK cell therapy, including the planned Phase 3 pivotal trial in autoimmune disease. The decision follows updated longer-term data showing clinical response durability below the threshold needed to continue development, plus two recent Grade 5 (fatal) events, including a case of leukoencephalopathy assessed as likely fludarabine toxicity. The FDA had asked Artiva to pause enrollment and dosing in the Phase 2a study.
Key figures
- Cash Position
- 319100000
- Grade 5 safety events
- 2
- Majority of costs expected
- Q4 2026
- Wind down completion timing
- workforce reduction expected complete in Q1 2027
- Workforce reduction percent
- 94
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.